Overview
The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.
Eligibility
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Is at least 6-weeks postpartum at the time of administration of study drug, following the delivery of a healthy singleton neonate
- Is willing and able to express breast milk using an electric pump prior to study drug administration and is expected to be able to express at least 4 times over a 24-hour period after study drug administration
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, psychiatric, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has had mastitis within 30 days prior to administration of study drug